WO2012078760A1 - Self-assembling hydrogels based on dicephalic peptide amphiphiles - Google Patents
Self-assembling hydrogels based on dicephalic peptide amphiphiles Download PDFInfo
- Publication number
- WO2012078760A1 WO2012078760A1 PCT/US2011/063747 US2011063747W WO2012078760A1 WO 2012078760 A1 WO2012078760 A1 WO 2012078760A1 US 2011063747 W US2011063747 W US 2011063747W WO 2012078760 A1 WO2012078760 A1 WO 2012078760A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gly
- seq
- dicephalic
- cells
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Definitions
- the invention relates to dicephalic peptide amphiphiles.
- the invention further relates to self-assembled hydrogels prepared from dicephalic peptide amphiphiles.
- Therapeutic delivery of proteins and cells, such as stem cells is currently accomplished by either systemic administration or bolus injection at the injury site. In both cases, only a relatively small percentage of active remains at the injury site and the bulk of the active end up in other organs like the liver and the lungs. An approach in which the actives are retained at the injury site would allow for lower dosage, less side effects and potentially higher activity.
- Self-assembling peptide systems have the benefit that when designed properly, they can be in a liquid state ex situ and rapidly transform into a gel state when in contact with body fluid in situ. Since the gelation mechanism is based on non-covalent interactions, no harm to proteins and cells is expected.
- a system based on peptides with alternating hydrophobic and charged residues has been reported that self-assemble due to beta sheet type hydrogen-bonding interactions between the peptides. The potential drawback of these systems is that it relies on a delicate balance in charge which limits the scope of accessible sequences.
- Hydrogels based on Fmoc-protected diphenylalanine are prepared by injecting a solution of the peptide in hexafluoroisopropanol, an undesirable solvent and there may also be concerns about the toxicity of the Fmoc protecting group upon degradation of the peptide.
- a variant was reported in which Fmoc-protected phenylalanine is coupled to phenylalanine by an enzyme. Potential drawbacks are potential immune response to the enzyme and a slower reaction rate.
- Systems based on beta hairpin peptides have been reported that are introduced by shear-thinning through a cannula after which they re-form.
- amphiphiles There are four major classes of amphiphiles: linear amphiphiles (single head, single tail), bola-amphiphiles (head-tail-head), gemini amphiphiles (two head groups, two tails) and dicephalic amphiphiles (two head groups, one tail). It has been shown that these classes exhibit different aggregation behavior compared to one another.
- An advantage of gemini and dicephalic amphiphiles is that they are 'pre-polymerized' and therefore form stable aggregates at lower critical aggregation concentrations.
- Gemini amphiphiles based on multiple positively charged peptides have been reported for use as gene transfection agents.
- Three dicephalic amphiphile systems are described hereafter. The first reported system comprises an amphiphile with a diphosphate head group that forms rectangular micellar aggregates. The two other systems have ammonium or saccharide head groups and form micelles.
- dicephalic amphiphiles having peptide sequences as the head groups. These dicephalic peptide amphiphiles are useful in preparing self-assembly hydrogels.
- the peptide head groups induce gelation and increase solubility of the amphiphile in aqueous solutions, while the hydrophobic tail serves to stabilize the hydrogel.
- these hydrogels are useful for the encapsulation and delivery of bioactives to a patient.
- Figure 1 Chemical drawing of an exemplary dicephalic peptide amphiphile.
- Figure 2. Schematic of dicephalic tail synthesis.
- Figure 3. Self-supporting gels of 2 wt% Gly-Phe-Gly-Phe-Gly-Phe-Gly-Gln-Gln-Ser DP A in DMEM.
- Figure 4 Chemical structure depicting possible calcium binding groups of Val-Ala-Val-Ala- Val-Ala-Glu-Glu-Glu DPA.
- Figure 5 Comparison of G' for the hydrogels with Glu-Gly-Glu sequence in the solubility enhancing region and self-assembly inducing regions containing either beta-sheet type hydrogen- bonding units or pi-pi stacking units.
- Figure 6. Time sweep comparison of gels with different polar, non-charged amino acids in the solubility enhancing region in PBS.
- Figure 7. Time sweep comparison of different polar, non-charged amino acids in the solubility enhancing region in DMEM.
- Figure 10 Cell viability of hUTC cells in Gly-Phe-Gly-Phe-Gly-Phe-Gly-Gln-Gln-Ser DP A gels after 3 weeks of culture. Insert shows 'dead' image, main picture the live cells.
- Figure 12 Cell viability of IMAC cells in Gly-Phe-Gly-Phe-Gly-Phe-Gly-Ser DPA gels after 3 weeks of culture.
- Figure 13 Histology of test articles at week 7.
- dicephalic peptide amphiphiles which form self-assembling hydrogels.
- the general structure of the dicephalic peptide amphiphile is shown below by the following Formula 1 :
- n is the length of the hydrocarbon chain designated by n.
- X is a peptide sequence, such as SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, shown in Table 1.
- n is the range of about 6 to about 22. In another embodiment, n is in the range of about 12 to about 18.
- the dicephalic peptide amphiphile has a hydrophobic tail and two peptide head groups.
- the hydrophobic tail provides stabilization to the hydrogel after self-assembly and the two head groups (X from Formula 1 above) have a peptide sequence.
- the peptide sequence has a self- assembly inducing region and a solubility enhancing region ( Figure 1), with the tail connecting to the N-terminus of the self-assembly inducing region.
- the self-assembly inducing region which provides directional secondary interactions to induce fiber formation and gelation has at least 4 amino acids. In one embodiment, the self-assembly inducing region has from about 6 to about 9 amino acids.
- the self-assembly inducing region is a peptide sequence, such as SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, and SEQ ID NO: 24.
- the directional secondary interactions provided by the self-assembly inducing region include, but are not limited to beta-sheet type hydrogen bonding and pi-pi stacking interactions.
- beta-sheet type hydrogen bonding and pi-pi stacking interactions One example of a self-assembly inducing region having the beta-sheet type hydrogen bonding interactions is Val-Ala-Val-Ala-Val-Ala.
- Aromatic sequences that have the pi-pi stacking type interactions include Gly-Phe-Gly-Phe-Gly-Phe-Gly, Gly-Phe-Gly-Phe-Gly-Phe-Gly-Phe-Gly, Gly-Tyr-Gly-Tyr-Gly-Tyr-Gly, Gly-Trp-Gly-Trp-Gly-Trp-Gly, and the like.
- the last sequence did not result in gels but large aggregates are formed.
- the hydrogels prepared from DP As which were driven by pi-pi stacking interactions displayed rheological properties that were an order of magnitude larger than the hydrogels prepared from DP As which were driven by beta-sheet hydrogen bonding interactions at the same concentration of amphiphile.
- the self-assembly inducing region provides pi- pi stacking interactions and has the peptide sequence Gly-Phe-Gly-Phe-Gly-Phe.
- the solubility enhancing region enables solubility of the dicephalic peptide amphiphile and plays a role in the kinetics of hydrogel formation.
- the solubility enhancing region has at least 1 amino acid, and in one embodiment, has at least 3 amino acids. In another embodiment, the solubility enhancing region has 3 amino acids.
- the solubility enhancing region has peptide sequences rich in polar residues that enhance solubility of the DPA in solution, for example in water, phosphate buffered saline, DMEM and the like.
- Suitable peptide sequences for the solubility enhancing region include, but are not limited to Glu-Gly-Glu, Glu-Glu-Glu, Gln-Gln- Ser, Asn-Asn-Ser, Gln-Gly-Ser, Gly-Gln-Ser, Asn-Gly-Ser, Gly-Asn-Ser, Glu-Gly-Ser and Lys- Gly-Ser.
- a Lys- Ala peptide sequence proved to be insoluble with the self-assembly inducing regions that were tested and therefore only peptide sequences with 3 or more polar amino acids were pursued.
- the solubility enhancing region is a peptide sequence, such as SEQ ID NO: 26 SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.
- solubility enhancing region can be extended with peptide sequences displaying biological activity.
- Dicephalic peptide amphiphiles were prepared in a three-step process. First the dicephalic tail was prepared by reacting fatty acid chloride (having a hydrocarbon chain length
- the peptide sequence was prepared using solid state peptide synthesis technique, either manually or by automated synthesis.
- the dicephalic tail was coupled to the peptide while still on the resin, using a taikpeptide mole ratio of 1 :2. Interestingly, attempts to prepare a variant with only one peptide per tail failed, presumably because the dicephalic version is entropically favored.
- the dicephalic peptide amphiphile is cleaved from the resin and protecting groups on the peptide side chains are removed in a single step by treatment with trifluoroacetic acid (TFA).
- TFA trifluoroacetic acid
- the molecules are then dissolved in water and lyophilized at pH 6-8 to remove residual acid.
- hydrogels resulting from the dicephalic peptide amphiphiles exhibit fluid-like properties ex situ whereas it will transform into a hydrogel encapsulating the bioactive in situ without denaturing or otherwise negatively affecting the activity of the bioactives.
- These hydrogels are useful for the therapeutic delivery of bioactives through small gauge cannulas. The gel will then retain the bioactives at the injury site such that the bioactives can exert their therapeutic action.
- hydrogels are prepared by dissolving the dicephalic peptide amphiphile at double the desired final hydrogel concentration in aqueous solution (water, phosphate buffered saline etc.) having a pH from about 5 to about 9, followed by mixing with physiological salt solutions (such as phosphate buffered saline, Hank's balanced salt solution, Dulbecco's Modified Eagle media), cell media (mixtures of aforementioned physiological salt solutions and serum) or physiological fluids (such as synovial fluid, spinal fluid).
- physiological salt solutions such as phosphate buffered saline, Hank's balanced salt solution, Dulbecco's Modified Eagle media
- cell media mixturetures of aforementioned physiological salt solutions and serum
- physiological fluids such as synovial fluid, spinal fluid.
- hydrogels that display shear-thinning behavior are prepared directly by dissolving the dicephalic peptide amphiphile in physiological salt solutions.
- Final dicephalic peptide amphiphile concentrations can range from about 1 percent by weight up to the limit of solubility.
- the concentration of ions should be such that it is sufficient to neutralize the charges in the solubility enhancing region.
- a four weight percent dicephalic peptide amphiphile solution in water and a 1 : 1 mixing ratio with physiological salt solution is used, although other ratios may be used as long as the concentration of ions is sufficient to neutralize the charge of the solubility enhancing region of the peptide.
- the electrostatic repulsion between the terminal acid groups partially counter-acts the self-assembly, leading to small assemblies. Gelation occurs upon mixing because the ions screen the surface charge resulting in fiber elongation followed by gelation. Rheological comparison showed that salt concentration affects the kinetics of formation.
- the dicephalic peptide amphiphile can be dissolved by selecting the pH such that the terminal amino acid is charged. Gelation can then be induced by modifying the pH such that the charge of the terminal amino acid in the solubility enhancing region becomes neutralized.
- two or more dicephalic peptide amphiphiles with different peptide sequences are mixed and induce to gel with any of the described methods.
- the rheological properties of the gel keep improving over time, reflecting the dynamic nature of the gel: the initial kinetically trapped structure re-organizes in the thermodynamically more stable form. After 30-60 minutes, a structure close to optimal seems to have been achieved.
- the dicephalic hydrogels prepared as described above are useful for the delivery of bioactive agents including, but not limited to cells, proteins, and oligonucleotides in a minimally invasive fashion.
- bioactive agents including, but not limited to cells, proteins, and oligonucleotides in a minimally invasive fashion.
- the benign mechanism of cross-linking does not interfere with the biological function of the incorporated active whereas the low viscosity of the gel precursor solution allow for introduction in a minimally invasive fashion.
- Dicephalic peptide amphiphile hydrogels that are extended with bioactive sequences might also be useful to capture circulating bioactives, perform signaling events, modulate cell behavior such as factor secretion etc.
- Suitable cell types that could be encapsulated include, but are not limited to stem cells, progenitor cells, primary cells, transfected cells and immortalized cells.
- human umbilical tissue derived cells were encapsulated.
- human kidney derived cells were encapsulated.
- human mammary artery cells were encapsulated.
- tissue fragments or minced tissue can be encapsulated.
- Suitable proteins include, but are not limited to antibodies and growth factors.
- Suitable oligonucleotides include but are not limited to siRNA and microRNA .
- delivery of cells can be achieved by mixing the dissolved dicephalic peptide amphiphile at double the final concentration in a 1 : 1 ratio with a cell suspension in the cell appropriate media.
- 100 microliters of a 4 weight% dicephalic peptide amphiphile solution is mixed with 100 microliters of a cell suspension containing 100,000 cells.
- Cell concentrations are limited by the maximum cell density in the cell suspension.
- the number of cells encapsulated in the gel range from about 10,000 cells to about 1,000,000 cells. There is no appreciable reduction of cell viability over the course of three weeks for a variety of cell types.
- Delivery of the cell containing formulations in vivo can be achieved in a number of ways. Not limiting the possibilities, one could use a dual barreled syringe with one chamber containing the dicephalic peptide amphiphile solution in water and the other chamber containing the cell suspension. One can then either use a single or dual lumen cannula depending on where one wants mixing to occur. Alternatively, one can make use of the shear-thinning properties and preform the gel in a single barrel syringe. Upon injection, the gel will shear-thin and pass through the cannula after which it re-forms in vivo.
- biocompatibility of three different formulations Val-Ala-Val-Ala- Val-Ala-Glu-Gly-Glu, Gly-Phe-Gly-Phe-Gly-Phe-Gly-Glu-Gly-Glu and Gly-Phe-Gly-Phe-Gly-Phe-Gly- Phe-Gly-Gln-Gly-Gln was evaluated by injecting 100 microliter of gel into a pocket that was created in the intra-gluteal muscle. After 28 days, no gel could be detected in any of the groups. Over the course of the experiment, the Gly-Phe-Gly-Phe-Gly-Phe-Gly-Gln-Gly-Gln formulation showed no tissue response. However, the other two formulations, requiring supraphysiological calcium concentration to gel, showed necrosis of the underlying muscle tissue.
- the synthesis of the tail was performed on a multi-gram scale ( ⁇ 5 g starting material) and starts from the methyl ester of 2-amino-malonic acid and palmitoyl chloride ( Figure 2).
- the coupling of palmitoyl chloride to 2-amino-malonic acid in chloroform was achieved in 92% yield.
- the product was purified by subsequent extractions with hydrochloric acid, 10% sodium bicarbonate and water. Subsequently, ester hydrolysis in ethanol was performed by reflux for 2 hours in the presence of excess potassium hydroxide. Purification was performed by a series of extractions with hydrochloric acid, saturated sodium chloride solution and water.
- deprotection and amino acid coupling steps was repeated until all amino acid residues were coupled.
- Deprotection was achieved by adding 5 cc of 20% piperidine in dimethylformamide (DMF) and shaking for 5 minutes followed by draining the deprotection cocktail. This was repeated twice for a total of three deprotection steps.
- NMP N-methylpyrrolidone
- coupling was performed by dissolving 1 mmol (2-(lH-Benzotriazol-l-yl)-l, 1,3,3- tetramethyluronium hexafluorophosphate) (HBTU) in 5 cc NMP which was subsequently added to 1 mmol amino acid.
- the mixture was incubated room temperature for 5 minutes after which 0.3 cc diisopropylethylamine was added. The mixture was then added to the resin and shaken for 1 hour. After an NMP wash, the next cycle was performed.
- the tail was added by the following procedure. 70 mg HBTU was dissolved in 5 cc NMP and added to 40 mg tail (prepared as described in Example 1). The mixture was sonicated briefly to facilitate dissolution of the tail. Next, 0.1 cc
- the peptide was dissolved in 10-20 cc water by pH adjustment. Once the dicephalic peptide amphiphile was completely dissolved, the pH was adjusted to 6-8, after which the dicephalic peptide amphiphile was lyophilized.
- the tail was added by the following procedure. 70 mg HBTU was dissolved in 5 cc NMP and added to 40 mg tail (prepared as described in Example 1). The mixture was sonicated briefly to facilitate dissolution of the tail. Next, 0.1 cc
- Deprotection of the side chains and cleavage from the resin was achieved by shaking for 3-4 hours with 10 cc 95%> trifluoroacetic acid(TFA)/2.5%> triisopropylsilane/2.5%) water.
- TFA trifluoroacetic acid
- the TFA mixture was drained from the peptide synthesis vessel and collected in a round bottom flask. The resin was washed twice with 1 cc TFA and the fractions were combined. After evaporation of the TFA until a minimal volume remained, the peptide was precipitated with a 10- fold excess of cold diethyl ether. Alternatively, the TFA was completely removed and the residual dicephalic peptide amphiphile was triturated for 30 minutes with 50 cc diethylether.
- the dicephalic peptide amphiphile was collected by filtration. Subsequently the dicephalic peptide amphiphile was dissolved in 10-20 cc water by pH adjustment. Once the dicephalic peptide amphiphile was completely dissolved, the pH was adjusted to 6-8, after which the dicephalic peptide amphiphile was lyophilized.
- the dicephalic peptide amphiphiles (DP As) having the peptide sequences shown in Table 1 have been synthesized using the methods described above in Examples 1-3.
- a linear peptide amphiphile analogue to the DPA with SEQ ID NO 8 similar to those reported in the art was created by the automated synthesis route as described in Example 2 with the modification that palmitoyl acid was used as the tail in a 1 : 1 molar ratio to the peptide on the resin instead of the dicephalic tail.
- the Gly-Phe- Gly-Phe-Gly-Phe-Gly-Gln-Gln-Ser peptide was prepared by automated peptide synthesis.
- Example 4 Gelation experiments Inversion tests were performed to determine qualitatively under which conditions the various DPAs formed self-supporting hydrogels.
- the various types of DP As were tested by dissolving them in ultrapure water (>18 ⁇ resistivity) at double the desired final concentration followed by mixing in a 1 : 1 ratio with different liquid mediums. Gelation was deemed to have occurred if the gel supported its own weight upon inverting the vial (Figure 3). Gelation was tested at final concentrations of 1, 2 and 4 weight percent.
- PBS phosphate buffered saline
- DMEM Dulbecco's modified eagle media
- Val-Ala-Val-Ala-Val-Ala-Glu-Glu-Glu and Gly-Val-Ala-Val-Al-Glu-Gly- Glu DPAs formed gels at minimal concentrations of 2 weight percent in DMEM with calcium added, whereas the Gly-Phe-Gly-Phe-Gly-Phe-Gly-Glu-Gly-Glu DPA formed a gel at a minimal concentration of 1 weight percent (Table 4). Gels were self-supporting when inverted to mix, optically transparent and after two months had not disintegrated nor expelled water. After this finding, supported by rheology (vide supra), self-assembly inducers based on aromatic amino acids were used exclusively.
- the Gly-Phe-Gly-Phe-Gly-Phe-Gly-Phe-Gly-Gln-Gln-Ser DPAs form self-supporting gels at 4 wt% in water after approx. 5 minutes. These gels can be disrupted by vortexing, after which they reform when left alone. Similarly, qualitatively better gels can be prepared by dissolving them in PBS rather than water. When mixed with DMEM, these DPAs form gels at 2 wt% without addition of supplemental calcium ions (Table 5). It is postulated that using polar, non-charged amino acids in the solubility enhancing region removes the need for extra calcium and allows for gelation at physiological salt concentrations.
- the Gly-Trp-Gly-Trp-Gly-Trp-Gly-Trp-Gly-Gln-Gln-Ser DPA was prepared since it was anticipated that a larger aromatic moiety would provide stronger pi-pi stacking interactions. However, both in the case of Gly-Trp-Gly-Trp-Gly-Trp-Gly-Gln-Gln-Ser and Gly-Trp-Gly-Trp- Gly-Gly-Gln-Gln-Ser DPAs, no gelation was observed under conditions tested (2-4 wt%, water, PBS, DMEM and DMEM plus calcium).
- Gly-Tyr-Gly-Tyr-Gly-Tyr-Gly-Tyr-Gly-Gln-Gln-Ser DPA does form gels when mixed with DMEM and calcium but does not gel in water, PBS or DMEM (Table 6). Therefore, it was concluded that phenylalanine is the preferred residue in terms of the efficiency of aromatic stacking. Tryptophan and Tyrosine may still work at different spacing between the aromatic amino acids.
- Gly-Phe-Gly-Phe-Gly-Phe-Gly-Phe-Gly-Asn-Asn-Ser DPA was prepared to see whether a shorter side chain would be beneficial. This DPA displays similar gelation characteristics compared to Gly-Phe-Gly-Phe-Gly-Phe-Gly-Gln-Gln-Ser DPA. In addition, Gly-Phe-Gly-Phe-Gly-Phe-Gly-Gly- Gln-Gly-Ser DPA was prepared to test whether reduced intramolecular steric hindrance would be beneficial. The gel formed more rapidly and appears to be stronger.
- Val-Ala-Val-Ala-Val-Ala-Glu-Glu-Glu DPA was titrated with calcium ions to determine the number of acid groups that required ion complexation in order for gelation to occur. Theoretically, there are eight acid groups (four per head group) that could be involved in the gelation process (Figure 4). Titrating down from 16 to 1 equivalent by halving the amount of calcium showed that the transition point between stable gel formation and no or weak gel formation occurred between two and one equivalent of calcium.
- Example 6 Rheology to evaluate the mechanical properties of DPA hydrogels.
- Oscillating rheology by the parallel plates method was performed on 400 ⁇ gels to assess the mechanical strengths of gels.
- Time sweeps were performed to evaluate kinetics of formation at a constant strain rate of 1% and frequency of 1 rad/s. Strain sweeps were performed ranging from 1-100% strain in increments of 2% at a constant frequency of 1 rad/s. Cross-over of G' and G" was used to determine the gel point and point of breakdown. Time sweeps were initiated immediately after mixing the solutions that lead to DPA hydrogel formation. In the strain sweeps, the gels were allowed to form on the plate for 30 minutes before the measurement is initiated.
- the G" curve remains flat after 1 minute, but G' keeps increasing for at least one hour showing the dynamic nature of the gel which allows re-arrangement from the initial kinetic structure to the thermodynamically favored structure ( Figure 5).
- the G' of the 2 wt% Gly-Phe-Gly-Phe-Gly-Phe-Gly-Glu-Gly-Glu DPA gel is an order of magnitude larger (4,000 Pa after 10 minutes) than the 1 wt% Gly-Phe-Gly-Phe- Gly-Phe-Gly-Glu-Gly-Glu DPA (300 Pa) and the 2 wt% Gly-Val-Ala-Val-Ala-Val-Ala-Glu-Gly- Glu DPA (140 Pa).
- the gels keep improving in properties and the order of strength in terms of DPA sequence in the solubility enhancing region is Asn-Asn-Ser > Gln-Gly-Ser > Gln-Gln- Ser.
- the DPA gel with the Asn-Asn-Ser sequence in the solubility enhancing region had the highest initial strength, but showed a more rapid decline in properties (decline starts at 15% strain rather than 33 and 50%) and re-crossed the transition point before the others (42% strain rather than 99% strain).
- hUTCs human umbilical cord cells
- hKDC human kidney derived cells
- Encapsulation of the cells in the gels was achieved by adding 100 ⁇ cell suspension to 100 ⁇ of a 4 wt% DPA solution in ultrapure in a 24 well plate, resulting in a final DPA concentration of 2%.
- the gels were incubated for lh at 37 °C, 5% C0 2 after which 1000 ⁇ media was added on top of the gel. Cells were incubated at 37 °C, 5% C0 2 . Every 3-4 days of culture, 500 ⁇ media was replaced.
- the cells were cultured for 3 weeks and cells were assessed after 1 , 2 and 3 weeks with Live/Dead. At all time points, very limited numbers of dead cells were detected, showing that viability remains good over the whole time period ( Figure 11).
- IMACs internal mammaray artery
- IMACs human internal mammary artery derived cells
- Encapsulation of the cells in the gels was achieved by adding 100 ⁇ cell suspension to 100 ⁇ of a 4 wt% DPA solution in ultrapure in a 24 well plate, resulting in a final DPA concentration of 2%.
- the gels were incubated for lh at 37 °C, 5% C0 2 after which 1000 ⁇ media was added on top of the gel.
- Cells were incubated at 37 °C, 5% C0 2 . Every 3-4 days of culture, 500 ⁇ media was replaced. The cells were cultured for 3 weeks and cells were assessed after 1 , 2 and 3 weeks with
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR112013014203A BR112013014203A2 (en) | 2010-12-08 | 2011-12-07 | bisphenic amphiphilic peptide, hydrogel and method for releasing a bioactive agent |
| CN201180059012.6A CN103502262B (en) | 2010-12-08 | 2011-12-07 | Self-assembled hydrogels based on double-headed amphiphilic peptides |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/962,775 | 2010-12-08 | ||
| US12/962,775 US8546338B2 (en) | 2010-12-08 | 2010-12-08 | Self-assembling hydrogels based on dicephalic peptide amphiphiles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012078760A1 true WO2012078760A1 (en) | 2012-06-14 |
Family
ID=45390207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/063747 Ceased WO2012078760A1 (en) | 2010-12-08 | 2011-12-07 | Self-assembling hydrogels based on dicephalic peptide amphiphiles |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US8546338B2 (en) |
| CN (1) | CN103502262B (en) |
| BR (1) | BR112013014203A2 (en) |
| WO (1) | WO2012078760A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014003679A1 (en) * | 2012-06-28 | 2014-01-03 | Anamar Ab | Determining pathological cartilage turnover |
| WO2016034728A1 (en) * | 2014-09-04 | 2016-03-10 | Cambridge Enterprise Limited | Protein capsules |
| US9700599B2 (en) | 2012-11-13 | 2017-07-11 | Adocia | Rapid-acting insulin formulation comprising a substituted anionic compound |
| US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
| US10525133B2 (en) | 2014-05-14 | 2020-01-07 | Adocia | Aqueous composition comprising at least one protein and one solubilizing agent, preparation thereof and uses thereof |
| US10792335B2 (en) | 2015-11-16 | 2020-10-06 | Adocia | Rapid-acting insulin composition comprising a substituted citrate |
| WO2020211504A1 (en) * | 2019-04-18 | 2020-10-22 | 福州大学 | Polypeptide hydrogel and preparation method therefor |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2864360B1 (en) | 2012-06-25 | 2017-09-06 | The Brigham and Women's Hospital, Inc. | Targeted therapeutics |
| CN108289926A (en) | 2015-10-14 | 2018-07-17 | 西北大学 | Nanofiber pastes for growth factor delivery and bone regeneration |
| WO2018075885A1 (en) | 2016-10-21 | 2018-04-26 | Northwestern University | Anti-microbial supramolecular structures |
| KR102223043B1 (en) * | 2018-09-28 | 2021-03-08 | 주식회사 히에라바이오 | Mesenchymal stem cells derived from synovium and uses thereof |
| JP7560884B2 (en) | 2019-01-24 | 2024-10-03 | ノースウエスタン ユニバーシティ | Supramolecular IKVAV intramatrix dynamics enhance functional maturation and regeneration of human IPSC-derived neurons |
| US12214076B2 (en) | 2019-02-18 | 2025-02-04 | Northwestern University | Drug delivery vehicles for atherosclerosis nanomedicine |
| CN111233979B (en) * | 2020-02-19 | 2026-04-03 | 四川大学华西医院 | A Gemini Amphiphilic Short Peptide and Its Application as a Hydrophobic Drug Carrier |
| US11998589B2 (en) | 2020-07-13 | 2024-06-04 | Northwestern University | PEGylated peptide amphiphile nanofibers and methods of use |
| US12247063B2 (en) | 2020-07-13 | 2025-03-11 | Northwestern University | Cell surface modification by coating with peptide amphiphiles (PAs) |
| US12116461B2 (en) | 2020-08-21 | 2024-10-15 | Northwestern University | Host-guest interactions for pa superstructure formation |
| CA3225407A1 (en) | 2021-07-29 | 2023-02-02 | Shelby Chi YUAN | Self-assembling peptide amphiphiles displaying a transforming growth factor beta 1 (tgf-.beta.1) mimetic epitope |
| CN115925798A (en) * | 2022-12-09 | 2023-04-07 | 中国海洋大学 | Small molecular peptide and its application in the preparation of drugs for inhibiting xanthine oxidase |
| CN116942889B (en) * | 2023-06-06 | 2024-02-02 | 广州图微科创生物科技有限公司 | Preparation method of hemostatic anti-adhesion polypeptide hydrogel |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999029712A1 (en) * | 1997-12-09 | 1999-06-17 | Smithkline Beecham Plc | Peptide-based gemini compounds |
| US20060241071A1 (en) * | 2003-06-16 | 2006-10-26 | Grinstaff Mark W | Functional synthetic molecules and macromolecules for gene delivery |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506806D0 (en) | 1995-04-01 | 1995-05-24 | Univ Leeds | Improvements relating to polymers |
| US6368877B1 (en) | 1997-06-25 | 2002-04-09 | Massachusetts Institute Of Technology | Self-assembling peptide surfaces for cell patterning and interactions |
| GB0025190D0 (en) | 2000-10-12 | 2000-11-29 | Smithkline Beecham Plc | Novel compounds |
| GB0031068D0 (en) | 2000-12-19 | 2001-01-31 | Smithkline Beecham Plc | Novel compounds |
| US7449180B2 (en) | 2001-02-06 | 2008-11-11 | John Kisiday | Macroscopic scaffold containing amphiphilic peptides encapsulating cells |
| US7491690B2 (en) | 2001-11-14 | 2009-02-17 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
| AU2003215280A1 (en) | 2002-02-15 | 2003-09-09 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
| US20060148734A1 (en) | 2002-03-27 | 2006-07-06 | Patrick Camilleri | Diaminoacid-aminoacid-polyamine based gemini surfactant compounds |
| WO2003084980A2 (en) | 2002-04-02 | 2003-10-16 | Northwestern University | Peptide amphiphile solutions and self assembled peptide nanofiber networks |
| WO2003090255A2 (en) | 2002-04-18 | 2003-10-30 | Northwestern University | Encapsulation of nanotubes via self-assembled nanostructures |
| WO2003096972A2 (en) | 2002-05-13 | 2003-11-27 | Massachusetts Institute Of Technology | Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof |
| WO2004003561A1 (en) | 2002-06-27 | 2004-01-08 | Northwestern University | Peptide rod amphiphiles and self-assembly of same |
| GB0216286D0 (en) | 2002-07-15 | 2002-08-21 | Univ Leeds | Network |
| WO2004007683A2 (en) | 2002-07-15 | 2004-01-22 | Massachusetts Institute Of Technology | Cellular reprogramming in peptide hydrogel and uses thereof |
| WO2004018628A2 (en) | 2002-08-21 | 2004-03-04 | Northwestern University | Charged peptide-amphiphile solutions & self-assembled peptide nanofiber networks formed therefrom |
| WO2004106359A2 (en) | 2002-09-23 | 2004-12-09 | Northwestern University | Self-assembled peptide-amphiphiles & self-assembled peptide nanofiber networks presenting multiple signals |
| US7554021B2 (en) | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
| US7683025B2 (en) | 2002-11-14 | 2010-03-23 | Northwestern University | Synthesis and self-assembly of ABC triblock bola peptide amphiphiles |
| US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| US7713923B2 (en) | 2003-06-25 | 2010-05-11 | Massachusetts Institute Of Technology | Self-assembling peptides incorporating modifications and methods of use thereof |
| EP2399990B1 (en) | 2003-06-27 | 2015-07-22 | DePuy Synthes Products, Inc. | Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system |
| US7966070B2 (en) | 2003-09-12 | 2011-06-21 | Medtronic, Inc. | Feedthrough apparatus with noble metal-coated leads |
| US7846891B2 (en) | 2003-10-17 | 2010-12-07 | Massachusetts Institute Of Technology | Self-assembling peptides for regeneration and repair of neural tissue |
| ES2380340T3 (en) | 2003-12-05 | 2012-05-10 | Northwestern University | Self-assembling peptide amphiphiles and related methods for the administration of growth factors |
| AU2004297211A1 (en) | 2003-12-05 | 2005-06-23 | Northwestern University | Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof |
| US7884185B2 (en) | 2004-07-28 | 2011-02-08 | University Of Delaware | Hydrogels and uses thereof |
| CN101150954A (en) | 2005-01-21 | 2008-03-26 | 西北大学 | Methods and compositions for encapsulating cells |
| GB0502482D0 (en) | 2005-02-07 | 2005-03-16 | Glaxo Group Ltd | Novel compounds |
| US9162005B2 (en) | 2005-04-25 | 2015-10-20 | Arch Biosurgery, Inc. | Compositions for prevention of adhesions and other barrier applications |
| EP1879606B1 (en) | 2005-04-25 | 2013-06-12 | Massachusetts Institute of Technology | Self-assembling peptides for promoting hemostasis |
| US7820028B2 (en) | 2005-09-02 | 2010-10-26 | Honeywell International Inc. | Oxides of nitrogen gas sensors and methods |
| GB0518220D0 (en) | 2005-09-07 | 2005-10-19 | Univ Manchester | Method of preparing a hydrogel |
| US8420605B2 (en) | 2005-09-07 | 2013-04-16 | The University Of Strathclyde | Hydrogel compositions |
| US10004828B2 (en) | 2005-10-11 | 2018-06-26 | Romat at Tel-Aviv University Ltd. | Self-assembled Fmoc-ff hydrogels |
| WO2007059491A2 (en) | 2005-11-14 | 2007-05-24 | University Of Delaware Technology Corporation | Novel hydrogels and uses thereof |
| CN101595212B (en) | 2006-10-12 | 2014-04-30 | 伊西康公司 | Kidney-derived cells and methods of use in tissue repair and regeneration |
| WO2008063808A2 (en) | 2006-10-24 | 2008-05-29 | Northwestern University | Encapsulated peptide amphiphile nanostructures |
| US8114835B2 (en) | 2006-11-09 | 2012-02-14 | Northwestern University | Self-assembling peptide amphiphiles for tissue engineering |
| US8114834B2 (en) | 2006-11-09 | 2012-02-14 | Northwestern University | Self-assembling peptide amphiphiles |
| WO2008121447A1 (en) | 2007-02-14 | 2008-10-09 | Northwestern University | Self-assembling membranes and related methods thereof |
| US8772228B2 (en) | 2007-02-14 | 2014-07-08 | Northwestern University | Aligned nanofibers and related methods of use |
| US9415084B2 (en) | 2007-03-14 | 2016-08-16 | Arch Biosurgery, Inc. | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix |
| US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
| US7906478B2 (en) | 2007-07-20 | 2011-03-15 | The Procter & Gamble Company | Personal-care articles having self-assembling peptides |
| US9714941B2 (en) | 2007-07-31 | 2017-07-25 | Massachusetts Institute Of Technology | Bio-sensing nanodevice |
| WO2009026233A2 (en) | 2007-08-17 | 2009-02-26 | Northwestern University | Self assembling peptide systems and methods |
| WO2009117497A1 (en) | 2008-03-19 | 2009-09-24 | University Of Delaware | Delivery of hydrogels as sprays |
| US8834926B2 (en) | 2008-08-08 | 2014-09-16 | University Of Delaware | Macromolecular diffusion and release from self-assembled β-hairpin peptide hydrogels |
| EP2318584A1 (en) | 2008-08-13 | 2011-05-11 | Dow Global Technologies LLC | Process of fabricating peptide-coated fibers |
| US8323972B2 (en) | 2009-09-30 | 2012-12-04 | Advanced Technologies And Regenerative Medicine, Llc | Mammary artery derived cells and methods of use in tissue repair and regeneration |
-
2010
- 2010-12-08 US US12/962,775 patent/US8546338B2/en active Active
-
2011
- 2011-12-07 CN CN201180059012.6A patent/CN103502262B/en active Active
- 2011-12-07 BR BR112013014203A patent/BR112013014203A2/en not_active IP Right Cessation
- 2011-12-07 WO PCT/US2011/063747 patent/WO2012078760A1/en not_active Ceased
-
2013
- 2013-02-06 US US13/760,531 patent/US20130129712A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999029712A1 (en) * | 1997-12-09 | 1999-06-17 | Smithkline Beecham Plc | Peptide-based gemini compounds |
| US20060241071A1 (en) * | 2003-06-16 | 2006-10-26 | Grinstaff Mark W | Functional synthetic molecules and macromolecules for gene delivery |
Non-Patent Citations (1)
| Title |
|---|
| TONY LE GALL ET AL: "Synthesis and Transfection Properties of a Series of Lipidic Neamine Derivatives", BIOCONJUGATE CHEMISTRY, vol. 20, no. 11, 18 November 2009 (2009-11-18), pages 2032 - 2046, XP055020341, ISSN: 1043-1802, DOI: 10.1021/bc900062z * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9632097B2 (en) | 2012-06-28 | 2017-04-25 | Nordic Boiscience A/S | Determining pathological cartilage turnover |
| AU2013281240B2 (en) * | 2012-06-28 | 2018-04-12 | Nordic Bioscience A/S | Determining pathological cartilage turnover |
| WO2014003679A1 (en) * | 2012-06-28 | 2014-01-03 | Anamar Ab | Determining pathological cartilage turnover |
| US10646551B2 (en) | 2012-11-13 | 2020-05-12 | Adocia | Rapid-acting insulin formulation comprising a substituted anionic compound |
| US11324808B2 (en) | 2012-11-13 | 2022-05-10 | Adocia | Rapid-acting insulin formulation comprising a substituted anionic compound |
| US9700599B2 (en) | 2012-11-13 | 2017-07-11 | Adocia | Rapid-acting insulin formulation comprising a substituted anionic compound |
| US10881716B2 (en) | 2012-11-13 | 2021-01-05 | Adocia | Rapid-acting insulin formulation comprising a substituted anionic compound |
| US10583175B2 (en) | 2012-11-13 | 2020-03-10 | Adocia | Rapid-acting insulin formulation comprising a substituted anionic compound |
| US10525133B2 (en) | 2014-05-14 | 2020-01-07 | Adocia | Aqueous composition comprising at least one protein and one solubilizing agent, preparation thereof and uses thereof |
| US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
| WO2016034728A1 (en) * | 2014-09-04 | 2016-03-10 | Cambridge Enterprise Limited | Protein capsules |
| US11878080B2 (en) | 2014-09-04 | 2024-01-23 | Cambridge Enterprise Limited | Protein capsules |
| US10792335B2 (en) | 2015-11-16 | 2020-10-06 | Adocia | Rapid-acting insulin composition comprising a substituted citrate |
| WO2020211504A1 (en) * | 2019-04-18 | 2020-10-22 | 福州大学 | Polypeptide hydrogel and preparation method therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103502262A (en) | 2014-01-08 |
| US20130129712A1 (en) | 2013-05-23 |
| BR112013014203A2 (en) | 2016-09-13 |
| US8546338B2 (en) | 2013-10-01 |
| CN103502262B (en) | 2015-11-25 |
| US20120148674A1 (en) | 2012-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8546338B2 (en) | Self-assembling hydrogels based on dicephalic peptide amphiphiles | |
| CN112789031B (en) | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery | |
| AU2014306021B2 (en) | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo | |
| CN103596594B (en) | self-gelling nucleic acid | |
| KR20140106511A (en) | Block copolymer having phenylboronic acid group introduced therein, and use thereof | |
| JP2019519508A (en) | Multi-arm polymerization target anticancer conjugate | |
| US20190328891A1 (en) | Medical preparation with a carrier based on hyaluronan and/or derivatives thereof, method of preparation and use thereof | |
| CA3084657A1 (en) | Cationic lipid | |
| Chakravarthy et al. | Temperature-induced nanostructure transition for supramolecular gelation in water | |
| CN106397545A (en) | Hydrogel material as well as preparation method and application thereof | |
| Zhang et al. | Biocompatible and pH-sensitive PEG hydrogels with degradable phosphoester and phosphoamide linkers end-capped with amine for controlled drug delivery | |
| CN117460542A (en) | Nanoparticles comprising peptide-lipid conjugates for delivering oligonucleotides into target cells and pharmaceutical compositions comprising the same | |
| CN110627912B (en) | A biomimetic fiber network antibody self-assembly material and its preparation method and application | |
| JPWO2019013255A1 (en) | Nucleic acid delivery composition and nucleic acid-containing composition | |
| CN114588254A (en) | Tumor neoantigen delivery system based on DNA origami and preparation method and application thereof | |
| JP2001515060A (en) | New lipopolyamines, their preparation and application | |
| EP3325527A1 (en) | Antiseptic polymer and synthesis thereof | |
| CN104069515B (en) | Paramagnetic metal complex modified by aspartic acid-leucine copolymer as well as preparation and application of paramagnetic metal complex | |
| WO2022028036A1 (en) | Self-assembling polypeptide, preparation method therefor, self-assembling polypeptide preparation and use thereof | |
| CN104083778B (en) | Paramagnetic metal complex that aspartic acid-phenylalanine copolymer is modified and its preparation method and application | |
| CN114573665B (en) | A chiral hemostatic polypeptide and its preparation method and application | |
| KR102369119B1 (en) | Method of production of graft co-polymer excipient with a superior peptide and protein binding property | |
| CN118105503A (en) | Synthesis and application of a protein-polymer self-assembly with multiple environmental stimulus responsiveness | |
| CN118108801A (en) | Polypeptide, hydrogel and application thereof | |
| DE102015000363A1 (en) | New modular functionalizable peptide hydrogels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11799566 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11799566 Country of ref document: EP Kind code of ref document: A1 |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013014203 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 112013014203 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130607 |









